戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ll disease (SCD) is a common, severe genetic blood disorder.
2  is an inherited, progressively debilitating blood disorder.
3 tory of the world's most prevalent heritable blood disorder.
4 herapeutic strategy against this devastating blood disorder.
5          Myelofibrosis (MF) is a devastating blood disorder.
6 a mechanosensitive ion channel involved in a blood disorder.
7 in the diagnosis and management of this rare blood disorder.
8 s and their derivatives for the treatment of blood disorders.
9 ZOs cause somatosensory, proprioceptive, and blood disorders.
10 d clinical trials for treating SCD and other blood disorders.
11 y of these effects across different types of blood disorders.
12 ce and for therapeutic strategies in genetic blood disorders.
13 an have potential impact on the treatment of blood disorders.
14 dy of serological responses in patients with blood disorders.
15 ons, inflammation, blood loss, and inherited blood disorders.
16 ells (HSPCs) holds great potential to remedy blood disorders.
17 enue for assessing, treating, and monitoring blood disorders.
18 editing in HSCs to treat inherited monogenic blood disorders.
19 ation in cellular immunotherapy of malignant blood disorders.
20 r mutations are responsible for a variety of blood disorders.
21 at is used to treat preleukemic and leukemic blood disorders.
22 tributed between malignant and non-malignant blood disorders.
23 mpanion Article to obtain the total costs of blood disorders.
24  from individuals without evidence of clonal blood disorders.
25 ic understanding of normal hematopoiesis and blood disorders.
26 ietic grafts to treat inherited and acquired blood disorders.
27  lymphocytic leukemia (CLL) and other clonal blood disorders.
28 y atherosclerosis, but also septic emboli or blood disorders.
29 velopment and provide new insight into human blood disorders.
30 spectrin tetramer formation, and may lead to blood disorders.
31 o the pathophysiology of cardiopulmonary and blood disorders.
32 o generate transplantable cells for treating blood disorders.
33 apeutic potential of RNAi for treating these blood disorders.
34 mportant target for the treatment of various blood disorders.
35 ed levels of engraftment for gene therapy of blood disorders.
36 t of patients with nonmalignant or malignant blood disorders.
37  to treat hematologic malignancies and other blood disorders.
38 ic approach for treatment of inherited human blood disorders.
39 sed therapy for hematologic malignancies and blood disorders.
40 to age-related macular degeneration and rare blood disorders.
41   In one form of beta-thalassemia, a genetic blood disorder, a mutation in intron 2 of the beta-globi
42 d to assess the economic burden of malignant blood disorders across the 28 countries in the European
43  assess the economic burden of non-malignant blood disorders across the 28 countries of the European
44 f myeloid-biased HSCs, with implications for blood disorders, aging, and immunity.
45 m underlying a variant form of the inherited blood disorder alpha thalassemia.
46 s a promising approach to permanently remedy blood disorders, although its application in engrafting
47 globin gene transfer in treating a fulminant blood disorder and strongly support the efficacy of gene
48  for the treatment and prevention of certain blood disorders and cancer.
49  cell distributions and vascular stresses in blood disorders and compare simulation results with expe
50 upregulated in a variety of human neoplastic blood disorders and constitutive upregulation of miR-125
51 esis, and cell transplantation as related to blood disorders and hematopoietic development.
52 udied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection.
53 e as a treatment modality to rectify genetic blood disorders and improve cellular therapies.
54 ity to infectious diseases, atherosclerosis, blood disorders and neurosensory disorders.
55                SCD is a frequently inherited blood disorder, and sickle cell anemia is a common type
56  effective treatment for leukemia, lymphoma, blood disorders, and autoimmune diseases.
57 nge of diseases including anaemia, malignant blood disorders, and haemorrhagic disorders.
58                                    Malignant blood disorders are a leading contributor to cancer inci
59                                   Congenital blood disorders are common and yet clinically challengin
60 ickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, p
61 ed in hemoglobin (Hb) AS and HbAC, inherited blood disorders associated with protection against sever
62 -globin, which are manifest in the inherited blood disorder beta thalassemia.
63                                          The blood disorder, beta-thalassaemia, is considered an attr
64 poietic cells from unrelated donors can cure blood disorders but carries a significant risk of acute
65 s, including acute leukaemias and congenital blood disorders, but obtaining suitable numbers of cells
66 ng factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing
67 genital, disease-associated, or drug-induced blood disorders can cause significant morbidities and mo
68      Sickle cell disease (SCD), an inherited blood disorder caused by a mutation in the beta-globin g
69         Beta-thalassemia is a severe genetic blood disorder caused by a mutation in the gene encoding
70      Sickle cell disease (SCD), an inherited blood disorder caused by mutation of the beta-globin gen
71 a (beta-Thal) is a group of life-threatening blood disorders caused by either point mutations or dele
72                          Porphyrias are rare blood disorders caused by genetic defects in the heme bi
73        beta-thalassemia (betaT) is a genetic blood disorder causing profound and life threatening ane
74 t Dana-Farber / Boston Children's Cancer and Blood Disorders Center.
75          Sickle cell disease is an inherited blood disorder characterized by chronic hemolytic anemia
76 ickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic anemia, episod
77  paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-me
78 urpura (iTTP) is a rare and life-threatening blood disorder characterized by the formation of blood c
79 CSAs) are a heterogeneous group of inherited blood disorders characterized by pathological mitochondr
80                                Patients with blood disorders colonized with antibiotic-resistant bact
81                                              Blood disorders comprise a wide range of diseases includ
82 costs in the EU (euro143 billion), malignant blood disorders cost euro12 billion (8%).
83              For the EU countries, malignant blood disorders cost euro6.8 billion (12%) of the total
84                                    Malignant blood disorders cost the 31 European countries euro12 bi
85                    Our study also shows that blood disorder costs were evenly distributed between mal
86                                              Blood disorders, diseases, and infections often affect t
87 c cell transplant (HCT) for the treatment of blood disorders, even with optimal donor HLA matching an
88 dies of allelic variation underlying genetic blood disorders have provided important insights into hu
89  disease (SCD), the most prevalent inherited blood disorder, have a higher risk of developing certain
90  these costs we added those due to malignant blood disorders (ICD-10 C81-96 and D47) as estimated in
91                    The most common inherited blood disorder in the world, sickle cell disease (SCD) i
92 ll disease (SCD) is a highly complex genetic blood disorder in which red blood cells (RBC) exhibit he
93       Sickle cell disease (SCD) is a genetic blood disorder in which red blood cells (RBCs) are const
94  assess the economic effect of non-malignant blood disorders in Europe.
95 efects in heme biosynthesis underlie several blood disorders in humans.
96 enzene is an industrial chemical that causes blood disorders, including acute myeloid leukemia.
97 ion of metabolism in HSCs results in various blood disorders, including leukemia.
98 the pathophysiology and treatment of several blood disorders, including the anaemia of renal disease.
99                         FMT in patients with blood disorders is safe and promotes eradication of ARB
100 ain impediments to effective gene therapy of blood disorders is the resistance of human hematopoietic
101                      Sickle cell anemia is a blood disorder, known to affect the microcirculation and
102    Sickle cell disease (SCD) is an inherited blood disorder marked by homozygosity of hemoglobin S, w
103 iesis, and its deregulation leads to various blood disorders, most importantly myeloproliferative neo
104  obesity, infectious disease susceptibility, blood disorders, neurosensory disorders, drug addiction
105 infection in immunocompromised patients with blood disorders or after bone marrow transplantation to
106 icity testing and treatment of patients with blood disorders or malignancies.
107 re results in a dramatic, cell-type-specific blood disorder phenotype.
108 ights the economic burden that non-malignant blood disorders place on European health-care systems an
109                                Non-malignant blood disorder-related costs (WHO International Classifi
110                                    Malignant blood disorder-related costs were estimated for 28 EU co
111                                    Malignant blood disorders represent a leading cause of death, heal
112                    Thalassemia, a hereditary blood disorder, requires regular blood transfusions, lea
113 ovide a new candidate for the rare inherited blood disorder stomatocytosis with uncompensated anemia.
114 ovascular, cerebrovascular, renal, liver, or blood disorders; substance dependency; and epilepsy.
115 ompartment could be used to treat congenital blood disorders such as beta-thalassemia.
116 g of the erythrocyte mechanics in hereditary blood disorders such as spherocytosis, elliptocytosis, a
117 a-globin mRNA and protein and to the genetic blood disorder thalassemia.
118     Sickle cell anemia (SCA) is an inherited blood disorder that causes morbidity and early mortality
119    Sickle cell disease (SCD) is a hereditary blood disorder that causes sickling of red blood cells u
120           Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occ
121 turnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bon
122         Sickle cell disease is a devastating blood disorder that originates from a single point mutat
123                   Thalassemias are inherited blood disorders that are found in high prevalences in th
124        Combining malignant and non-malignant blood disorders, the total cost of blood disorders was e
125 udies of various diseases, including cancer, blood disorders, thrombosis, inflammatory and autoimmune
126                       The "royal disease," a blood disorder transmitted from Queen Victoria to Europe
127 utations in these genes are commonly seen in blood disorders underscores their critical roles and hig
128 ietic stem cells (LT-HSCs) are used to treat blood disorders via stem cell transplantation.
129 malignant blood disorders, the total cost of blood disorders was euro23 billion in 2012.
130           For countries in the EU, malignant blood disorders were compared with the economic burden o
131 ifying disease-causing variants in Mendelian blood disorders were identified and implemented as AbFab
132 t patients had primary immunodeficiencies or blood disorders, while 4 others had abnormal immune func
133                                Patients with blood disorders who are immune suppressed are at increas
134 ll disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characte
135 ary platelet disorders (HPDs) are a group of blood disorders with variable severity and clinical impa

 
Page Top